

Datasheet for 200-401-AX8**DRAK2 Antibody****Overview**

Description:	Anti-DRAK2 (RABBIT) Antibody - 200-401-AX8
Item No.:	200-401-AX8
Size:	100 µg
Applications:	ELISA, IHC, WB
Reactivity:	Human
Host Species:	Rabbit

Product Details

Background:	Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases). DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues.
Synonyms:	DRAK2 Antibody, DRAK2, DRAK2, DAP kinase-related apoptosis-inducing protein kinase 2
Host Species:	Rabbit
Clonality:	Polyclonal
Format:	IgG

Target Details

Gene Name:	STK17B
Reactivity:	Human
Immunogen Type:	Conjugated Peptide
Immunogen:	Anti-DRAK2 antibody was prepared from whole rabbit serum produced by repeated immunizations with a 15 amino acid peptide near the C-terminus of human DRAK2.

Purity/Specificity:	Anti-DRAK2 Antibody is purified by ion exchange chromatography. It has no cross responses to DAP or ZIP kinases. The approximately 70 kDa band is probably non-related to DRAK2 although it is peptide blockable.
Relevant Links:	• UniProtKB - O94768 • GeneID - 9262 • NCBI - AB011421

Application Details

Tested Applications:	ELISA, IHC, WB
Application Note:	Anti-DRAK2 Antibody has been tested for use in ELISA, Western Blotting, Immunocytochemistry. Specific conditions for reactivity should be optimized by the end user. Expect a band at approximately 42 kDa in Western Blots of specific cell lysates and tissues.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
ELISA:	1:5,000
WB:	0.5 µg/mL


Formulation

Physical State:	Liquid (sterile filtered)
Concentration:	1 mg/mL by UV absorbance at 280 nm
Buffer:	0.01 M Sodium Phosphate, 0.25 M Sodium Chloride, pH 7.2
Preservative:	0.02% (w/v) Sodium Azide
Stabilizer:	None

Shipping & Handling


Shipping Condition:	Dry Ice
Storage Condition:	Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Expiration:	Expiration date is one (1) year from date of receipt.

Images



Immunocytochemistry

Immunocytochemistry of DRAK2 antibody. Cells: Jurkat cells. Fixation: formalin fixed paraffin embedded. Antigen retrieval: not required. Primary antibody: DRAK2 antibody at 10 µg/mL for 1 h at RT. Secondary antibody: Peroxidase rabbit secondary antibody at 1:10,000 for 45 min at RT. Localization: DRAK2 is nuclear and cytoplasmic. DRAK2 is also localized in the endoplasmic reticulum-Golgi intermediate compartment. Staining: DRAK2 as precipitated brown signal with hematoxylin purple counterstain.



Western Blot

Western Blot of DRAK2 antibody. Lane 1: Jurkat whole cell lysate. Lane 2: Raji whole cell lysate. Lane 3: Jurkat whole cell lysate in the presence of blocking peptide. Lane 4: Raji whole cell lysate in the presence of blocking peptide. Load: 35 µg per lane. Primary antibody: DRAK2 antibody at 1:500 for overnight at 4°C. Secondary antibody: Peroxidase rabbit secondary antibody at 1:10,000 for 45 min at RT. Block: 5% BLOTTO overnight at 4°C. Predicted/Observed size: 42.3 kDa, 42 kDa for DRAK2. Other band(s): DRAK2 splice variants and isoforms.

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.